Maresin-1 and its receptors RORα/LGR6 as potential therapeutic target for respiratory diseases. (August 2022)

• Record Type: Journal Article
• Authors: Zhao, Mengmeng; Li, Chenfei; Zhang, Jishou; Yin, Zheng; Zheng, Zihui; Wan, Jun; Wang, Menglong
• Is Part Of: Pharmacological research. Volume 182(2022)
• Publication Date: 2022-08
• Subjects: Maresin-1 -- RORα -- LGR6 -- Respiratory diseases -- Resolution; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106337
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Maresin-1 is one of the representative specialized pro-resolving mediators that has shown beneficial effects in inflammatory disease models. Recently, two distinct types of receptor molecules were discovered as the targets of maresin-1, further revealing the pro-resolution mechanism of maresin-1. One is retinoic acid-related orphan receptor α (RORα) and the another one is leucine-rich repeat domain-containing G protein-coupled receptor 6 (LGR6). In this review, we summarized the detailed role of maresin-1 and its two different receptors in respiratory diseases. RORα and LGR6 are potential targets for the treatment of respiratory diseases. Future basic research and clinical trials on MaR1 and its receptors should provide useful information for the treatment of respiratory diseases.